Please login to the form below

Not currently logged in
Email:
Password:

abuse-resistant

This page shows the latest abuse-resistant news and features for those working in and with pharma, biotech and healthcare.

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

This time the application included a Risk Evaluation Mitigation Strategy (REMS), stating that the drug must be administered by a trained healthcare professional to avoid substance abuse and accidental exposures. ... resistant. The drug is a new

Latest news

  • Endo faces industry-first FDA call to pull its opioid painkiller Endo faces industry-first FDA call to pull its opioid painkiller

    This action will protect the public from further potential abuse of this product,” she added. ... Previously Purdue Pharma’s opioid painkiller Oxycontin was removed from the market when an abuse-resistant form became available, but the privately-held

  • FDA panel backs Pfizer and Teva abuse-resistant painkillers FDA panel backs Pfizer and Teva abuse-resistant painkillers

    The two products are aimed at a market estimated to be worth around $2.5bn with several abuse-resistant products already on the market including Purdue Pharma's Hysingla ER and ... Pfizer already sells an abuse-resistant formulation of morphine called

  • Purdue gets FDA nod for abuse-deterrent painkiller Purdue gets FDA nod for abuse-deterrent painkiller

    Purdue Pharma has expanded its portfolio of opioid analgesic drugs following FDA approval of Hysingla ER, a once-daily product designed to resist abuse. ... Zogenix filed for approval of a line extension based on an abuse-resistant formulation in

  • Acura must provide FDA more info on pain drug Acura must provide FDA more info on pain drug

    Regulator questions abuse-resistant ability of Aversion. The FDA has demanded that Acura Pharmaceuticals submit more evidence on the abuse-deterrent abilities of its investigational pain drug. ... Acura is a company that specialises in developing

  • Teva expects big things from improved drug programme Teva expects big things from improved drug programme

    The first will be new opioid products for pain relief formulated with abuse-resistant properties - Teva has four of these in its pipeline - while the company is also developing new depot

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    News of rising resistant infections and the abuse of colistin in farming shows why we need to redouble our efforts to find new ways to treat drug-resistant infections. ... Microbes will continue to evolve to become resistant to new treatments in time, so

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Elite Pharma names Actavis VP as CEO Elite Pharma names Actavis VP as CEO

    to drive operational excellence and growth as we advance the development of products utilising our proprietary abuse resistant technology,” said Elite's chairman Jerry Treppel.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics